China CRISPR Market (2025-2030)
The China CRISPR Market was valued at $156.7 Million in 2025 and projected to reach to $286.9 Million by 2030, representing a compound annual growth rate of 12.9%. China's CRISPR market is poised for accelerated growth through 2030, driven by government prioritization of biotechnology as a strategic industry and increased R&D spending in genomic medicine.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
China CRISPR Market Trends and Insights
- China's rapid growth trajectory, driven by substantial government investment in genomic research and biotechnology infrastructure, positions the country as a critical hub for gene-editing innovation in Asia Pacific.
- The 12.9% compound annual growth rate reflects China's commitment to advancing precision medicine and therapeutic applications of CRISPR technology. China's CRISPR market benefits from a large patient population, increasing healthcare expenditure, and a growing number of clinical trials leveraging gene-editing platforms.
- China has emerged as a leader in CRISPR research commercialization, with domestic biotech firms and academic institutions accelerating development of CRISPR-based therapeutics.
- Between 2025 and 2030, China is expected to capture significant market share through regulatory approvals and expanded adoption across oncology, hematologic disorders, and genetic diseases. The competitive landscape in China reflects both domestic innovation and international partnerships, with Chinese enterprises increasingly competing alongside global players.
- China's supportive regulatory environment and talent pool continue to attract investment, ensuring sustained momentum in the CRISPR market through 2030..
Key Market Statistics
- CAGR (2025-2030) 12.9% CAGR
- Market Size, 2025 ~USD 156.7 Million
- Forecast, 2030 ~USD 286.9 Million
- Country China
China CRISPR Market Overview
Government-Backed Growth :
China's substantial government investment in genomic research and biotechnology infrastructure is accelerating CRISPR adoption, with national initiatives supporting gene-editing innovation across academic and commercial sectors.
Rapid Market Expansion :
China's CRISPR market is growing at 12.9% CAGR, outpacing the global rate of 11.2%, demonstrating the country's emerging leadership in gene-editing technology development and commercialization.
Asia Pacific Hub Status :
China is positioning itself as a critical hub for CRISPR innovation in the Asia Pacific region, attracting biotech investments and talent while establishing itself as a key player in global gene-editing markets.
Significant Market Valuation :
The Chinese CRISPR market is valued at $156.7 million in 2025 and is forecast to nearly double to $286.9 million by 2030, reflecting strong investor confidence and clinical pipeline development.
China CRISPR Market Dynamics
- The country's expanding ecosystem of biotech startups, research institutions, and manufacturing capabilities is creating a competitive advantage in gene-editing applications across oncology, rare genetic diseases, and infectious diseases. The 12.9% CAGR trajectory reflects China's commitment to reducing reliance on imported therapeutics while establishing domestic CRISPR-based treatment pipelines.
- Regulatory frameworks are evolving to support clinical trials, and partnerships between Chinese biotech firms and international players are accelerating technology transfer and commercialization timelines..
Related Ecosystem
Advanced Genetic Sequencing
- Polymerase Chain Reaction (PCR)
- Reagents
- Assay Kits
- Bioinformatics
- Flow Cytometry
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- Agilent Technologies, Inc.
- Qiagen N.V.
- Danaher Corporation
Key Takeaways
- China's CRISPR market is valued at $156.7 million in 2025 and is forecast to grow to $286.9 million by 2030, representing an 83% increase over five years.
- China's 12.9% CAGR outpaces the global average of 11.2%, reflecting accelerated adoption and government-backed genomic research initiatives.
- China's large patient population and expanding clinical trial infrastructure position the country as a key driver of CRISPR therapeutic development in Asia Pacific.
- China's domestic biotech ecosystem and supportive regulatory environment are attracting both local and international investment in gene-editing technologies.
CRISPR Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | GRNA SYNTHESIS & CELL LINE DEVELOPMENT (Service) |
| Forecast Period | 2025-2030 |
| Growth Rate | CAGR of 11.2% from 2025 to 2030 |
| Largest Segment | PRODUCT (Offering) |
| Market Size Base Year (Billions) | ~USD 3.22 (2025) |
| Revenue Forecast (Billions) | ~USD 5.47 (2030) |
| Segments Covered | Offering, Type, End User, Service, Application, Product |
China CRISPR Market Report Segmentation
6 segment dimensions are covered across the global market.
By Offering
- Product
- Products
- Service
- Services
By Type
- Crispr Kits & Enzymes
- Crispr Libraries
- Other Products
By End User
- Academic & Research Institutes
- Other End Users
- Pharmaceutical & Biotechnological Companies
- Pharmaceutical & Biotechnology Companies
By Service
- Grna Synthesis & Cell Line Development
- Other Services
- Screening & Validation
By Application
- Agriculture
- Drug Discovery & Development
- Other Applications
By Product
- Crispr Kits & Enzymes
- Crispr Libraries
- Other Products
CHINA: CRISPR SERVICES MARKET, BY END USER, 2023–2030
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 16 | 17.4 | 19.7 | 22.4 | 25.4 | 28.8 | 32.8 | 37.2 | 13.5 |
| OTHER END USERS | 17.4 | 18.8 | 21.1 | 23.7 | 26.7 | 30 | 33.8 | 38.1 | 12.6 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 21.2 | 23.2 | 26.4 | 30 | 34.2 | 38.9 | 44.3 | 50.5 | 13.9 |
| TOTAL | 54.6 | 59.5 | 67.1 | 76.2 | 86.3 | 97.8 | 110.9 | 125.9 | 13.4 |
CHINA: CRISPR PRODUCTS MARKET, BY END USER, 2023–2030
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 35 | 37.2 | 41.8 | 47.2 | 53.1 | 59.9 | 67.6 | 76.3 | 12.8 |
| OTHER END USERS | 46.5 | 49.4 | 55.4 | 62.4 | 70.1 | 78.9 | 88.9 | 100.2 | 12.6 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 49.6 | 52.8 | 59.5 | 67.4 | 76.2 | 86.1 | 97.5 | 110.4 | 13.2 |
| TOTAL | 131.1 | 139.4 | 156.7 | 177 | 199.5 | 224.9 | 254.1 | 286.9 | 12.9 |
Target Audience
- Biotech Companies : Biotech firms need China market intelligence to identify partnership opportunities, assess competitive threats, and develop localized CRISPR product strategies for the fastest-growing gene-editing market in Asia.
- Pharmaceutical Corporations : Large pharma companies require detailed China CRISPR data to evaluate in-licensing opportunities, plan clinical trial strategies, and determine optimal market entry timing in this high-growth segment.
- Investment Firms : Venture capital and private equity investors need comprehensive China CRISPR market analysis to identify promising startups, assess portfolio company growth potential, and allocate capital strategically.
- Healthcare Policy Makers : Government officials and healthcare administrators need market insights to inform reimbursement policies, regulatory frameworks, and healthcare infrastructure investments supporting CRISPR adoption in China.
- Research Institutions : Academic and research organizations need China market data to understand commercialization pathways, identify collaboration opportunities with Chinese institutions, and secure funding for CRISPR research programs.
Reasons to Buy this Report
- Market Entry Strategy : Understand China's unique regulatory landscape, government incentives, and competitive dynamics to develop effective market entry strategies for CRISPR-based products and services.
- Investment Opportunity Assessment : Evaluate the 12.9% CAGR growth potential and $130.2 million market expansion opportunity through 2030 to identify high-ROI investment targets in Chinese biotech firms and CRISPR platforms.
- Competitive Intelligence : Gain insights into China's emerging CRISPR players, research institutions, and manufacturing capabilities to benchmark competitive positioning and identify partnership or acquisition opportunities.
- Clinical Pipeline Analysis : Access detailed data on China-based CRISPR clinical trials, therapeutic applications, and regulatory approval timelines to inform product development and commercialization strategies.
- Government Policy Impact : Analyze how China's national genomic research initiatives and biotechnology subsidies influence market dynamics, enabling proactive adaptation to policy-driven growth catalysts.
Frequently asked questions
What is the current size of China's CRISPR market?
China's CRISPR market is valued at $156.7 million in 2025, with expectations to reach $286.9 million by 2030.
What is the projected growth rate for China's CRISPR market?
China's CRISPR market is projected to grow at a compound annual growth rate (CAGR) of 12.9% from 2025 to 2030.
What factors are driving growth in China's CRISPR market?
China's CRISPR market growth is driven by government investment in genomic research, a large patient population, increasing healthcare expenditure, and expanding clinical trial infrastructure.
How does China's CRISPR market growth compare to global trends?
China's CRISPR market CAGR of 12.9% exceeds the global average of 11.2%, indicating faster adoption and commercialization of gene-editing technologies in China.
What therapeutic areas are driving CRISPR adoption in China?
China's CRISPR market is expanding across oncology, hematologic disorders, and genetic diseases, supported by clinical trials and regulatory approvals.
RESEARCH METHODOLOGY
The research study utilized a range of secondary sources, directories, and databases to gather important information for analyzing the global CRISPR market. In addition, extensive interviews were conducted with various primary participants, including key industry members, subject-matter experts (SMEs), C-level executives from leading market players, and industry consultants. These interviews helped obtain and verify qualitative and quantitative information, allowing for a comprehensive evaluation of the market's growth scenarios. The global market size was estimated through secondary research, using both top-down and bottom-up approaches, followed by data triangulation that incorporated insights from industry experts to determine the final market size.
Secondary Research
Secondary research was primarily utilized to identify and gather information for the technical, market-oriented, and commercial analysis of the CRISPR market. The sources consulted for this study included the Broad Institute, Innovative Genomics Institute (IGI), National Institute of Food and Agriculture, International Chromosome and Genome Society (ICGS), National Human Genome Research Institute (NHGRI), Asia Pacific Society of Human Genetics (APSHG), Genetics Society of America (GSA), European Society of Human Genetics (ESHG), Centers for Common Disease Genomics (CDDG), Center for Cellular and Molecular Biology (CCMB) in India, and the Department of Biotechnology (DBT) in India.
Additional secondary sources comprised academic journals, company websites, corporate and regulatory filings such as annual reports, SEC filings, investor presentations, and financial statements; business magazines and research journals; press releases; and various trade, business, and professional associations. These sources were also instrumental in gathering essential information about key market players, market segmentation related to industry trends, developments at the regional and country levels, and technology prospects.
The secondary data collected was analyzed to determine the global CRISPR market size, which was subsequently validated through primary research.
Primary Research
Extensive primary research was conducted after gathering foundational knowledge about the global CRISPR market through secondary research. We carried out several primary interviews with market experts from both the demand and supply sides. On the demand side, we interviewed professionals from the pharmaceutical and biopharmaceutical industries, as well as from contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs). On the supply side, we spoke with C-level and D-level executives, product managers, and marketing and sales managers from key manufacturers, distributors, and channel partners.
The primary interviews were conducted across six major regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Approximately 65% of the interviews involved supply-side participants, while 35% were with demand-side participants. This primary data was collected through questionnaires, emails, online surveys, personal interviews, and telephone interviews.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were utilized to estimate and validate the overall size of the CRISPR market. These methods were also extensively employed to assess the sizes of various subsegments within the market. The research methodology for estimating the market size includes the following steps:
CRISPR Market : Top-Down and Bottom-Up Approach
Data Triangulation
After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) is a revolutionary tool used to edit genes in a way that resembles traditional GMO techniques. The use of the Cas9 enzymes differentiates CRISPR from other forms of genetic modification. CRISPR edits and rearranges genes by cutting out the damaged or unwanted part of the DNA, allowing the remaining DNA to be rearranged in a new way.
The report comprehensively analyzes the CRISPR market, covering a wide range of products & services such as CRISPR kits & enzymes, CRISPR libraries, gRNA synthesis, cell line development, and screening & validation.
Key Stakeholders
- Genome editing/genome engineering product manufacturers
- CRISPR editing/genome engineering product manufacturers
- Suppliers and distributors of genomic instruments/systems and consumables
- Contract manufacturing organizations
- Pharmaceutical and biotechnology companies
- Diagnostic centers and medical colleges
- Contract research organizations
- Government associations and research institutes
- Regulatory authorities
- Business research firms
Report Objectives
- To define, describe, and forecast the CRISPR market by offering, product, service, application, end user (products market), end user (services market), and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall CRISPR market
- To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players and analyze their market shares and core competencies
- To track and analyze competitive developments, such as product/service launches, partnerships, agreements, collaborations, and expansions
- To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:
Portfolio Assessment
- Product Matrix, which gives a detailed comparison of the product/service portfolios of the top three companies.
Company Information
- Detailed analysis and profiling of additional market players (up to three).
Geographical Analysis
- A further breakdown of the Rest of Asia Pacific CRISPR market into countries
- A further breakdown of the Rest of Europe CRISPR market into countries
- A further breakdown of the Rest of Latin America CRISPR market into countries
Get the Full CRISPR Market Report
Full forecast, segment splits, and company analysis for all CRISPR Market.
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report